Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-3025PMID 17575218
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUES

  2007cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007cited by this paper
• CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

  2006cited by this paper
• Molecular imaging of proliferation in malignant lymphoma.

  2006cited by this paper
• Positron-emission tomography and assessment of cancer therapy.

  2006cited by this paper
• Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.

  2005cited by this paper
• Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods.

  2005cited by this paper
• [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors

  2005cited by this paper
• Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

  2005cited by this paper
• FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

  2005cited by this paper
• The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels

  2005cited by this paper
• Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

  2005cited by this paper
• Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy

  2005cited by this paper
• Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.

  2004cited by this paper
• Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

  2004cited by this paper
• Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3′-Fluoro-3′-Deoxy-l-Thymidine

  2004cited by this paper
• 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.

  2003cited by this paper
• Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

  2003cited by this paper
• 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.

  2003cited by this paper
• Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.

  2003cited by this paper
• Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.

  2002cited by this paper
• Positron Emission Tomography for the Staging of Hodgkin's Lymphoma - Increasing the Body of Evidence in Favor of the Method

  2002cited by this paper
• Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

  2002cited by this paper
• Early changes in [18F]FLT uptake after chemotherapy: an experimental study

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

  2001cited by this paper
• Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?

  2001cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.

  2001cited by this paper
• Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

  2001cited by this paper
• World Health Organization classification of tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT

  2000cited by this paper
• Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT)

  2000cited by this paper
• 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.

  1999cited by this paper
• Reproducibility of metabolic measurements in malignant tumors using FDG PET.

  1999cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

  1999cited by this paper
• Imaging proliferation in vivo with [F-18]FLT and positron emission tomography

  1998cited by this paper
• Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome.

  1998cited by this paper
• Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.

  1998cited by this paper
• Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.

  1998cited by this paper
• Extranodal malignant lymphoma: detection with FDG PET versus CT.

  1998cited by this paper
• Carbon-11-thymidine and FDG to measure therapy response.

  1998cited by this paper
• IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

  1997cited by this paper
• Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

  1997cited by this paper
• Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake.

  1994cited by this paper

• Nuclear medicine in hematology: Bridging diagnostics and therapy

  2025cites this paper
• Co-encapsulation of Vincristine and Vitamin E in Soy Lecithin/Hydrogenated Soy Lecithin Liposomes

  2025cites this paper
• Emerging Role of [18F]FLT PET/CT in Lymphoid Malignancies: A Review of Clinical Results

  2024influential citation
• PET/CT and PET/MRI, Normal Variations, and Artifacts

  2020cites this paper
• Selumetinib ( AZD 6244 , ARRY ‐ 142886 ) in Patients with Solid Tumors

  2019cites this paper
• 18F-FDG and 11C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study

  2019cites this paper
• 3′-Deoxy-3’-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies

  2019cites this paper
• Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial

  2019cites this paper
• An Overview of PET Radiopharmaceuticals in Clinical Use: Regulatory, Quality and Pharmacopeia Monographs of the United States and Europe

  2018cites this paper
• Imaging Potential Evaluation of Fab Derived from the Anti-EGFRvIII Monoclonal Antibody 4G1

  2018cites this paper
• Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response

  2018cites this paper
• Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging

  2018cites this paper
• 18 F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer

  2018cites this paper
• Role of PET/CT in Pediatric Malignancy

  2017cites this paper
• Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma

  2017cites this paper
• A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT

  2017cites this paper
• A pilot study for texture analysis of 18F-FDG and 18F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery

  2017cites this paper
• Diagnostic applications of nuclear medicine: Lymphomas

  2017cites this paper
• Instructions for use Title Assessment of early changes in H-3-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression

  2017cites this paper
• FLT PET/CT-Guided Biopsy in the Evaluation of Cancer

  2016cites this paper
• A method for quantitative total marrow imaging (QTMI) with PET/CT

  2016cites this paper
• A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients.

  2016cites this paper
• Cancer Imaging for Therapy Assessment

  2016cites this paper
• Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.

  2016cites this paper
• Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts

  2016cites this paper
• Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using ( 18 F)Fluorothymidine-PET

  2015cites this paper
• Prognostic Value Comparison Between 18F-FLT PET/CT and 18F-FDG PET/CT Volume-Based Metabolic Parameters in Patients with Head and Neck Cancer

  2015cites this paper
• 18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer

  2015cites this paper
• The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy

  2015cites this paper
• Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors

  2015cites this paper
• Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy

  2015cites this paper
• Imaging tumour proliferation with [F-18]fluorothymidine PET in patients with non-small cell lung cancer in response to radiotherapy

  2015cites this paper
• PET/CT imaging in cancer: Current applications and future directions

  2014cites this paper
• Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma

  2014cites this paper
• Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL

  2014cites this paper
• Cancer Biology: What’s Important for Imaging

  2014cites this paper
• Physiologic Uptake, Variants, and Pitfalls

  2014cites this paper
• FLT PET-CT in evaluation of treatment response

  2014cites this paper
• Clinical translation of molecular imaging agents used in PET studies of cancer.

  2014cites this paper
• 18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair

  2014cites this paper
• Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.

  2014cites this paper
• Early Determination of Prognosis by Interim 3′-Deoxy-3′-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma

  2014cites this paper
• FDG-PET imaging for Hodgkin lymphoma: current use and future applications.

  2014cites this paper
• Predictive value of SUV-based parameters derived from pre-treatment 18F-FLT PET/CT for short-term outcome with head and neck cancers

  2014cites this paper
• Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma

  2014cites this paper
• The role of F-18-fluorothymidine PET in oncology

  2013cites this paper
• PET Imaging of Proliferation with Pyrimidines

  2013cites this paper
• 18F-Fluorothymidine-Pet Imaging of Glioblastoma Multiforme: Effects of Radiation Therapy on Radiotracer Uptake and Molecular Biomarker Patterns

  2013cites this paper
• Introduction to the analysis of PET data in oncology

  2013cites this paper
• Sveriges lantbruksuniversitet Immunohistochemical detection of thymidine kinase 1 in canine mammary tumours and lymphomas

  2013cites this paper
• Managing Lymphoma with Non-FDG Radiotracers: Current Clinical and Preclinical Applications

  2013cites this paper
• Development of (18)F-labeled PET probes for imaging cell proliferation.

  2013cites this paper
• Positron emission tomography/CT in the management of lymphoma

  2013cites this paper
• Immunohistochemical detection of thymidine kinase 1 in canine mammary tumors and lymphomas

  2013cites this paper
• Update on pediatric leukemia and lymphoma imaging.

  2013cites this paper
• Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma.

  2013cites this paper
• 18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients.

  2013cites this paper
• Imaging and radiation therapy: Current trends and future possibilities

  2013cites this paper
• Changes in 18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy

  2013cites this paper
• 3′‐deoxy‐3′‐[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma

  2012cites this paper
• Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

  2012cites this paper
• Impact of the Definition of Peak Standardized Uptake Value on Quantification of Treatment Response

  2012cites this paper
• Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition.

  2012cites this paper
• Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the Future

  2012cites this paper
• [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment.

  2012cites this paper
• The Feasibility of 18F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer

  2012cites this paper
• AACR Cancer Progress Report 2012

  2012cites this paper
• Usefulness of 3′-Deoxy-3′-18F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

  2012cites this paper
• PET imaging: implications for the future of therapy monitoring with PET/CT in oncology.

  2012cites this paper
• Novel PET Radiotracers for Potential Use in Management of Lymphoma.

  2012cites this paper
• 18F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors

  2012cites this paper
• Molecular imaging for personalized cancer care

  2012cites this paper
• New PET radiopharmaceuticals beyond FDG for brain tumor imaging.

  2012cites this paper
• [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner

  2012cites this paper
• FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.

  2012cites this paper
• Positron emission tomographic scans in lymphoma: convention and controversy.

  2012cites this paper
• Hitting the target in MCL.

  2012cites this paper
• for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

  2012cites this paper
• Comparison of 18 F-FLT PET and 18 F-FDG PET for detection of cervical lymph node metastases in head and neck cancers

  2012cites this paper
• Usefulness of 3 9 -Deoxy-3 9 - 18 F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

  2012cites this paper
• Assessment of Response to Therapy

  2012cites this paper
• Validation of 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography for image-guidance in biologically adaptive radiotherapy

  2012cites this paper
• Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy

  2012cites this paper
• PET for Initial and Early Response Imaging in Mantle Cell Lymphoma

  2011cites this paper
• A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma

  2011cites this paper
• Development of radiotracers for oncology – the interface with pharmacology

  2011cites this paper
• 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.

  2011cites this paper
• Imaging Techniques in Drug Development and Clinical Practice

  2011cites this paper
• Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.

  2011cites this paper
• Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers

  2011cites this paper
• Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F–FLT–PET study

  2011cites this paper
• [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel

  2011cites this paper
• Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment

  2011cites this paper
• FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.

  2011influential citation
• Role of functional imaging in the management of lymphoma.

  2011cites this paper
• A method for assessing voxel correspondence in longitudinal tumor imaging.

  2011cites this paper
• Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.

  2011cites this paper
• Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer

  2011cites this paper
• A Novel In Vitro Assay to Assess Phosphorylation of 3′-[18F]fluoro-3′-Deoxythymidine

  2011cites this paper
• Increase of [18F]FLT Tumor Uptake In Vivo Mediated by FdUrd: Toward Improving Cell Proliferation Positron Emission Tomography

  2011cites this paper